Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

63.46
-0.6700-1.04%
Post-market: 63.460.00000.00%19:30 EDT
Volume:895.55K
Turnover:56.95M
Market Cap:5.30B
PE:-104.03
High:65.40
Open:64.81
Low:62.80
Close:64.13
52wk High:90.87
52wk Low:61.23
Shares:83.46M
Float Shares:73.65M
Volume Ratio:0.72
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-32.03
PE(LYR):8.16

Loading ...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Werewolf Therapeutics Posts Q2 Profit on Jazz Asset Sale

Reuters
·
Jul 31

PTC Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

PTC Therapeutics Director Hege Elisabeth Sollie-Zetlmayer Files Initial Beneficial Ownership Statement

Reuters
·
Jul 31

PTC Therapeutics Raises Outlook on Strong Q2 Results

TIPRANKS
·
Jul 31

PTC Therapeutics Posts Corporate Presentation Highlighting Sephience PKU Launch Momentum

Reuters
·
Jul 31

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B

MT Newswires Live
·
Jul 31

Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24

MT Newswires Live
·
Jul 31

PTC Therapeutics Q2 FY26 Net Income Swings to $83.5 Million; Revenue More than Doubles to $361 Million

Reuters
·
Jul 31

PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate

Benzinga Earnings
·
Jul 31

PTC Therapeutics Q2 EPS USD 0.92

THOMSON REUTERS
·
Jul 31

PTC Therapeutics: Total Product Revenue Guidance Raised to $850 to $950 Million for FY 2026

THOMSON REUTERS
·
Jul 31

PTC Therapeutics Q2 Net Income USD 83.496 Million

THOMSON REUTERS
·
Jul 31

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

MT Newswires Live
·
Jul 27

Earning Preview: PTC Therapeutics Q2 revenue is expected to increase by 74.33%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

THOMSON REUTERS
·
Jul 23

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Personalis (PSNL) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 20

PTC Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 20

PTC Therapeutics price target lowered to $93 from $95 at Wells Fargo

TIPRANKS
·
Jul 20